Agile Therapeutics Inc. [AGRX] Stock trading around $0.54 per share: What’s Next?

Related

Agile Therapeutics Inc. [NASDAQ: AGRX] stock went on an upward path that rose over 8.22% on Tuesday, amounting to a one-week price decrease of less than -6.78%. The company report on July 12, 2022 that Agile Therapeutics Updates Second Quarter 2022 Guidance.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range.

Over the last 12 months, AGRX stock dropped by -98.79%. The one-year Agile Therapeutics Inc. stock forecast points to a potential upside of 99.46. The average equity rating for AGRX stock is currently 2.50, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $7.40 million, with 3.12 million shares outstanding. Compared to the average trading volume of 9.93M shares, AGRX stock reached a trading volume of 7577225 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Agile Therapeutics Inc. [AGRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGRX shares is $100.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGRX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for Agile Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Janney raised their target price to Buy. The new note on the price target was released on April 12, 2019, representing the official price target for Agile Therapeutics Inc. stock. Previously, the target price had yet another raise to $3, while Maxim Group analysts kept a Buy rating on AGRX stock.

The Average True Range (ATR) for Agile Therapeutics Inc. is set at 0.17, with the Price to Sales ratio for AGRX stock in the period of the last 12 months amounting to 1.30. The Price to Book ratio for the last quarter was 0.90.

AGRX Stock Performance Analysis:

Agile Therapeutics Inc. [AGRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.78. With this latest performance, AGRX shares dropped by -53.04% in over the last four-week period, additionally sinking by -95.79% over the last 6 months – not to mention a drop of -98.79% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGRX stock in for the last two-week period is set at 36.66, with the RSI for the last a single of trading hit 36.77, and the three-weeks RSI is set at 35.21 for Agile Therapeutics Inc. [AGRX]. The present Moving Average for the last 50 days of trading for this stock 1.0873, while it was recorded at 0.5541 for the last single week of trading, and 12.9683 for the last 200 days.

Insight into Agile Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Agile Therapeutics Inc. [AGRX] shares currently have an operating margin of -1731.41 and a Gross Margin at -32.11. Agile Therapeutics Inc.’s Net Margin is presently recorded at -1826.24.

Return on Equity for this stock declined to -255.62, with Return on Assets sitting at -133.27.

Agile Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.50 and a Current Ratio set at 0.60.

Agile Therapeutics Inc. [AGRX] Insider Position Details

There are presently around $11 million, or 8.30% of AGRX stock, in the hands of institutional investors. The top three institutional holders of AGRX stocks are: PERCEPTIVE ADVISORS LLC with ownership of 21,294,485, which is approximately 3900.001% of the company’s market cap and around 0.10% of the total institutional ownership; ARMISTICE CAPITAL, LLC, holding 113,678 shares of the stock with an approximate value of $57000.0 in AGRX stocks shares; and VANGUARD GROUP INC, currently with $48000.0 in AGRX stock with ownership of nearly -13.735% of the company’s market capitalization.

Positions in Agile Therapeutics Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 16 institutional holders increased their position in Agile Therapeutics Inc. [NASDAQ:AGRX] by around 20,893,162 shares. Additionally, 26 investors decreased positions by around 75,968 shares, while 11 investors held positions by with 800,956 shares. The mentioned changes placed institutional holdings at 21,770,086 shares, according to the latest SEC report filing. AGRX stock had 5 new institutional investments in for a total of 114,639 shares, while 15 institutional investors sold positions of 48,000 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]